ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
epix · stock forecast · 5 analysts (3M) · FMP · updated Nov 14, 2025
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Hold
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$17.00
Consensus
$9.50
+4621.7% upside
Low
$2.00
Median: $9.5 · Last Close: $0.20
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.20 | ↑ 0.19% |
1-day model range: $0.2–$0.21. Peak: $0.21 (+0.19%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · EPIX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-04 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2024-11-04 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2024-11-01 | Jones Trading | Downgrade ↓ | Buy→Hold |
| 2024-05-16 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-12-13 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-08-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-05-12 | Piper Sandler | Maintains | Overweight→Overweight |
| 2021-08-17 | Oppenheimer | Maintains | Outperform→Outperform |
| 2021-03-04 | Piper Sandler | Maintains | Overweight→Overweight |
| 2021-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ESSA Pharma Inc. (EPIX) stock. Of the recent 14 rating actions, 0 were upgrades and 3 were downgrades. 5 analysts currently cover EPIX.
Analyst Recommendation Trends
EPIX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$22M
EPS This Year
$-0.71
EPS Next Year
$-0.49
↓ 31.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast EPIX EPS of $-0.71 for the current fiscal year, based on estimates from 1 analysts. The EPIX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EPIX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EPIX price target is $9.50 (+4621.7% upside), with an analyst consensus of Hold.
The EPIX short-term stock prediction for tomorrow is $0.20 (+0.19%).
ESSA Pharma Inc. trades on NASDAQ under the ticker EPIX. The EPIX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
EPIX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month EPIX price target is $9.50, with a high forecast of $17.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +4621.7% potential upside from the current price of $0.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.